Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507774 | 0.85 | KMT2A (0.44) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL6940786 | 0.85 | KMT2A (0.44) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL13812977 | 0.80 | GABBR2 (0.51) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL13812973 | 0.78 | KMT2A (0.50) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL29991645 | 0.78 | KMT2A (0.50) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL4065318 | 0.78 | KMT2A (0.50) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL2622288 | 0.78 | GABBR2 (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL22184570 | 0.78 | KMT2A (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL4687405 | 0.77 | LMNA (0.39) | KMT2AMEN1MERTKSYK | |
| SCHEMBL27225170 | 0.77 | KMT2A (0.49) | KMT2AMEN1GABBR2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390921-A | Heterocyclic compound with cyclin-dependent kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230042936-A1 | PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (F.S.P. CNIO) (ES) | 2023-02-09 | — | — | US | disclosed |
| WO-2021183994-A1 | PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | PROSENESTAR LLC (US) | 2021-09-16 | — | — | WO | disclosed |
| EP-1268476-A1 | 5-ALKYLPYRIDO[2,3-D]PYRIMIDINES TYROSINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070741-A1 | 5-ALKYLPYRIDO[2,3-D]PYRIMIDINES TYROSINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042936-A1 | PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | CDK7, CDK8, CDK9 | KMT2A 397/4885MEN1 2207/4885GABBR2 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.